Pharmacological and non-pharmacological treatments for chronic Chagas cardiomyopathy remain largely based on extrapolations of existing evidence rather than disease-specific trial data.
This review highlights the current diagnostic and therapeutic landscape for chronic Chagas cardiomyopathy, emphasizing that most pharmacological treatments are extrapolated from general heart failure guidelines and underscoring the need for dedicated trials in this population.
Chagas disease has become globalized as a result of the migratory process of infected patients to non-endemic areas. With the considerable number of individuals affected by the disease, detection and treatment of its chronic manifestations is a relevant and necessary issue. Growing attention has been paid to chronic Chagas cardiomyopathy (CCC), which includes heart failure, malignant arrhythmias, conduction disturbances and thromboembolic events. Many pharmacological and non-pharmacological treatments for CCC are still extrapolations of existing evidence on the treatment of ...
Martins et al. (Thu,) conducted a review in Chronic Chagas cardiomyopathy. Pharmacological and non-pharmacological treatments for chronic Chagas cardiomyopathy remain largely based on extrapolations of existing evidence rather than disease-specific trial data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: